StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
RTW.L$2.19-0.45%
Fair $2.19+0.0%

RTW.L

RTW Biotech Opportunities Ltd

Financial Services / Asset ManagementLSE

$2.19

-0.01 (-0.45%)

Fairly Valued+0.0%Fair Value $2.19Fund rank 22/100 · Data gapFallback financials|
SA 38/D
F-Score: 5/9

Book/ROE base 3Y

n/d

n/d CAGR · P/B n/d

Book/ROE base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 100% · confianza 20%

Book/ROE escenarios

weak_data · book/share n/d · quality 50.0/100

Data gap 22/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 17/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

38/100

D

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); financial Book/ROE targets are disabled until manually verified.
Thesis & Journal · RTW.LLocal privado en este navegador · RTW Biotech Opportunities Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$709M

P/E

0.0x

↓

EV/EBITDA

N/A

•

ROE

28.3%

↑

Gross Margin

N/A

•

Debt/Equity

N/A

•
52-Week Range$2
$1$2

TradingView lightweight chart

RTW.L price, volumen y niveles de valoración

Último $2.190Periodo +110.6%
Fair value: $2.190

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

+116.6%

FCF margin

42.0%

FCF / Net income

0.43x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $250.9M · net income $245.2M · FCF $105.3M

2022-FY → 2025-FY

Gross margin

—— pts

Operating margin

—— pts

Net margin

97.7%-10.3% pts

FCF margin

42.0%+70.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$250.9M$250.9M$38.7M$86.3M$-36.5M
Net Income$245.2M$245.2M$34.2M$83.2M$-39.4M
EPS0.630.630.110.36-0.17
Net Margin97.7%97.7%88.3%96.4%108.0%
Balance Sheet
Current Ratio1.661.66———
Cash Flow
Free Cash Flow$105.3M$105.3M$-124.3M$33.5M$10.4M
Returns
ROE28.3%28.3%5.4%19.4%-11.3%
Valuation
P/E0.030.0313.093.83—
P/B0.990.990.710.740.83
Growth & Yield
Revenue Growth547.8%547.8%-55.1%336.4%—
EPS Growth472.7%472.7%-69.4%311.8%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-32.4%

fácil

EPS terminal req.

$0.19

Spread vs growth

505.2%

5Y implied EPS CAGR

-17.9%

fácil

EPS terminal req.

$0.24

Spread vs growth

490.6%

10Y implied EPS CAGR

-5.0%

fácil

EPS terminal req.

$0.38

Spread vs growth

477.7%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +85.6%

Total return

+85.6%

Start / end P/E

10.7x → 3.5x

EPS bridge

0.11 → 0.63

Residual

-319.5%

EPS growth+472.7%
Multiple rerating-67.6%
Dividend+0.0%
Residual / FX / buybacks / cross-term-319.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.